Invention Grant
- Patent Title: Benzimidazolone derived inhibitors of BCL6
-
Application No.: US16616901Application Date: 2018-05-25
-
Publication No.: US12110286B2Publication Date: 2024-10-08
- Inventor: Benjamin Richard Bellenie , Michael K. Carter , Kwai Ming Jack Cheung , Owen Alexander Davis , Swen Hoelder , Matthew Garth Lloyd , Ana Varela Rodriguez , Hannah Woodward , Paolo Innocenti
- Applicant: Cancer Research Technology Limited , The Institute of Cancer Research: Royal Cancer Hospital
- Applicant Address: GB London
- Assignee: Cancer Research Technology Limited,The Institute of Cancer Research
- Current Assignee: Cancer Research Technology Limited,The Institute of Cancer Research
- Current Assignee Address: GB London; GB London
- Agency: Goodwin Procter LLP
- Priority: GB 08502 2017.05.26 GB 06130 2018.04.13
- International Application: PCT/GB2018/051447 2018.05.25
- International Announcement: WO2018/215801A 2018.11.29
- Date entered country: 2019-11-25
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D401/12 ; C07D403/12 ; C07D403/14 ; C07D405/14 ; C07D409/14 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D471/08 ; C07D487/04
Abstract:
The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
Public/Granted literature
- US20210147382A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Public/Granted day:2021-05-20
Information query
